Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2209 articles about Gilead Sciences, Inc.
-
Gilead Sciences to Present at Upcoming January 2024 Investor Conference
12/21/2023
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference.
-
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
12/21/2023
HOOKIPA Pharma Inc. announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share.
-
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
12/19/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.
-
Israel-based cancer immunotherapy company Compugen will receive $60 million upfront from Gilead for the license to its antibody, which blocks the interaction between the IL-18 binding protein and IL-18.
-
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
12/11/2023
Gilead Sciences, Inc. announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index for the third consecutive year.
-
ASH 23: CAR-T for Autoimmune, Arcellx's Multiple Myeloma Challenger and Seagen's Combo Play
12/11/2023
A CAR-T cell therapy for autoimmune diseases generated significant attention at the 2023 American Society of Hematology (ASH) annual meeting and Arcellx and Seagen posted promising data. -
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
11/30/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy ® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
-
The agency on Tuesday said it is investigating the “serious risk” of T cell malignancy outcomes, including hospitalization and death, and evaluating the need for potential regulatory action.
-
Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas
11/21/2023
Claudia Hardy says she's found her life's mission. As director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham - the only National Cancer Institute-Designated Cancer Center in the state - she brings cancer resources and preventive care to communities in Alabama's Black Belt like the one she grew up in.
-
Kite and Arcellx Announce Expansion in Strategic Partnership
11/15/2023
Kite, a Gilead Company, and Arcellx, Inc., announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.
-
Arcellx and Kite Announce Expansion in Strategic Partnership
11/15/2023
Arcellx, Inc. and Kite, a Gilead Company, announced that the companies have expanded their existing collaboration, which was originally announced in December 2022.
-
Months after the FDA lifted its partial hold on their Phase II multiple myeloma program, Kite and Arcellx are expanding their existing development and commercialization collaboration in the blood cancer space.
-
Gilead Sciences to Present at Upcoming November 2023 Investor Conferences
11/9/2023
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences.
-
Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research
11/9/2023
Gilead Sciences / Dr. Shringar Rao's inquisitive nature and dedication to addressing health inequities drive her eagerness to help advance innovative scientific breakthroughs.
-
The third-quarter growth of Gilead’s HIV, oncology and cell therapy businesses was completely offset by declining COVID-19 and liver disease sales, with revenue flat compared to the same period last year.
-
Gilead Sciences: Advancing Global Health Equity in Tropical Regions
11/7/2023
Gilead Sciences / In the late 1980s, people in Dr. Shyam Sundar's homeland in eastern India were dying by the hundreds of thousands of a debilitating parasitic disease known as visceral leishmaniasis.
-
Gilead Sciences Announces Third Quarter 2023 Financial Results
11/7/2023
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
-
A combination of Gilead Sciences’ domvanalimab and Arcus Biosciences’ zimberelimab, along with chemo, has shown an “encouraging” overall response rate in a mid-stage study.
-
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
11/6/2023
Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study.
-
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
11/3/2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, from November 10-14, 2023.